These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35574239)

  • 1. Screening for inhibitors against SARS-CoV-2 and its variants.
    Yuan W; Dong X; Chen L; Lei X; Zhou Z; Guo L; Wang J
    Biosaf Health; 2022 Jun; 4(3):186-192. PubMed ID: 35574239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1.
    Kuzikov M; Woens J; Zaliani A; Hambach J; Eden T; Fehse B; Ellinger B; Riecken K
    Biomed Pharmacother; 2022 Jul; 151():113104. PubMed ID: 35643072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders.
    Chuang ST; Buchwald P
    Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants.
    Li Y; Xu S; Ye Q; Chi H; Guo Z; Chen J; Wu M; Fan B; Li B; Qin CF; Liu Z
    Adv Sci (Weinh); 2023 Jan; 10(2):e2202689. PubMed ID: 36377484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.
    Zhu Y; Dong X; Liu N; Wu T; Chong H; Lei X; Ren L; Wang J; He Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1819-1827. PubMed ID: 35786417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro.
    Ngwe Tun MM; Sakura T; Sakurai Y; Kurosaki Y; Inaoka DK; Shioda N; Smith C; Yasuda J; Morita K; Kita K
    Trop Med Health; 2022 Apr; 50(1):30. PubMed ID: 35477500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
    Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Zhou H; Møhlenberg M; Thakor JC; Tuli HS; Wang P; Assaraf YG; Dhama K; Jiang S
    Clin Microbiol Rev; 2022 Sep; 35(3):e0001422. PubMed ID: 35862736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
    Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
    J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the Impact of Mutations on the Binding Efficacy of SARS-CoV-2 Omicron and Delta Variants With Human ACE2 Receptor.
    Khan A; Khan SA; Zia K; Altowyan MS; Barakat A; Ul-Haq Z
    Front Chem; 2022; 10():892093. PubMed ID: 35755247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
    Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
    J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
    Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
    BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease.
    Stevaert A; Van Berwaer R; Mestdagh C; Vandeput J; Vanstreels E; Raeymaekers V; Laporte M; Naesens L
    mBio; 2022 Aug; 13(4):e0137622. PubMed ID: 35913162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants.
    Alonzi T; Aiello A; Repele F; Falasca L; Francalancia M; Garbuglia AR; Delogu G; Nicastri E; Piacentini M; Goletti D
    Cell Death Discov; 2022 Jun; 8(1):288. PubMed ID: 35705564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.